One Liberty Properties, a real estate investment trust, has agreed to purchase a four-building industrial portfolio in Milwaukee for $34 million. The portfolio spans 277,117 square feet, is fully leased to seven tenants across diverse industries, and generates about $2.3 million in annual base rent with rent increases of 2% to 4%. The acquisition, expected to close in Q4 2026, will be funded by cash and a $20.6 million mortgage. This deal increases One Liberty's 2026 acquisitions to over $102 million and strengthens its industrial property focus in a low-vacancy Milwaukee market with strong manufacturing demand.
One Liberty Properties' recent industrial portfolio purchase provides context for the real estate market. For readers following US real estate stocks, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: Out of 47 priced Real Estate-sector US stocks tradable on Pluang, 35 rose and 12 fell today. Notable movers include WY (Weyerhaeuser Company Common Stock) at USD 21.21 with a 1-day change of +4.00%, CUBE (CubeSmart) at USD 42.57 with +3.70%, and EPR (EPR Properties) at USD 59.64 with +3.34%. Typical hold times vary from 1 to 84 days, with Pluang order activity showing significant selling pressure on CUBE and EPR.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NEAR governance approved a plan to reduce the maximum annual issuance of the NEAR token from 2.5% to 1.6%. This change aims to slow the rate at which new tokens enter circulation, potentially impacting staking rewards by lowering them. The plan inclu...
